RecruitingNot Applicable

Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure

United States270 participantsStarted 2026-04-30

Plain-language summary

RECOVER HF is a clinical study designed to evaluate the safety and efficacy of Synchronized Diaphragmatic Stimulation delivered using the VisONE System in the treatment of patients with heart failure.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Greater than mild mitral valve stenosis
✕. Greater than moderate mitral valve regurgitation
✕. Greater than mild tricuspid valve stenosis
✕. Greater than moderate-severe tricuspid valve regurgitation
✕. Greater than moderate aortic stenosis
✕. Greater than moderate aortic regurgitation
✕. Greater than mild-moderate pulmonic stenosis
✕. Greater than moderate pulmonic regurgitation

What they're measuring

Left ventricular End-Systolic Volume (LVESV)

Timeframe: 6 months

Six Minute Hall Walk (6MHW)

Timeframe: 6 months

Minnesota Living with Heart Failure quality of Life Score (MLWHF QOL)

Timeframe: 6 months

Major Adverse Respiratory and Cardiovascular Events (MARCE)

Timeframe: 6 months

Trial details

NCT IDNCT06552637

SponsorVisCardia Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-07

Contact for this trial

Patricia Arand, Ph.D.

5034313823 arandp@viscardia.com

View on ClinicalTrials.gov More Heart Failure With Reduced Ejection Fraction trials